Cancer treatment with biosimilar drugs:A review
作者机构：Department of MicrobiologyKalinga UniversityRaipurChhattisgarhIndia Institute of Pharmaceutical ResearchGLA UniversityMathuraUttar PradeshIndia Drug Testing LaboratoryAvam Anusandhan KendraRaipurChhattisgarhIndia
出 版 物：《Cancer Innovation》 (肿瘤创新（英文）)
年 卷 期：2024年第3卷第2期
页 面：45-62页
学科分类：1002[医学-临床医学] 100214[医学-肿瘤学] 10[医学]
主 题：biologics biosimilars cancer Escherichia coli monoclonal antibody next-generation sequencing pharmacovigilance
摘 要：Biosimilars are biological drugs created from living organisms or that contain living *** share an identical amino-acid sequence and *** drugs are considered to be cost-effective and are utilized in the treatment of cancer and other endocrine *** primary aim of biosimilars is to predict biosimilarity,efficacy,and treatment costs;they are approved by the Food and Drug Administration(FDA)and have no clinical *** involve analytical studies to understand the similarities and dissimilarities.A biosimilar manufacturer sets up FDA-approved reference products to evaluate *** contribution of next-generation sequencing is evolving to study the organ tumor and its progression with its impactful therapeutic approach on cancer patients to showcase and target rare *** study shall help to understand the future perspectives of biosimilars for use in gastro-entero-logic diseases,colorectal cancer,and thyroid *** also help target specific organs with essential mutational categories and drug prototypes in clinical practices with blood and liquid biopsy,cell treatment,gene therapy,recombinant therapeutic proteins,and personalized *** derivatives such as monoclonal antibodies like trastuzumab and rituximab are common drugs used in cancer *** coli produces more than six antibodies or antibody-derived proteins to treat cancer such as filgrastim,epoetin alfa,and so on.
维普期刊数据库